BI’s Cyltezo Becomes 15th EU Biosimilar This Year, Adds To Pressure On Humira
Executive Summary
Boehringer Ingelheim has received its first EU biosimilar approval: Cyltezo, a version of AbbVie’s blockbuster drug Humira. The product will not be launched until after expiry of the adalimumab SPC in October 2018.
You may also be interested in...
New Year Debut Of Another Biosimilar Humira In India
AbbVie may have managed to push back direct biosimilar competition to Humira (adalimumab) in the US by a few years, but 2018 has begun with the launch of yet another biosimilar of the blockbuster biologic in India. Hetero, the latest entrant, expects to maintain pricing parity with its peers on the domestic market.
New Year Debut Of Another Biosimilar Humira In India
AbbVie may have managed to push back direct biosimilar competition to Humira (adalimumab) in the US by a few years, but 2018 has begun with the launch of yet another biosimilar of the blockbuster biologic in India. Hetero, the latest entrant, expects to maintain pricing parity with its peers on the domestic market.
Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.